A cost-effectiveness analysis of reduced viral transmission with baloxavir marboxil versus oseltamivir or no treatment for seasonal and pandemic influenza management in the United Kingdom.
Svenn Alexander KommandantvoldAnnabelle Lemenuel-DiotChris SkedgelRichard PitmanPeter RouseHassan ZaraketHao ZhouMarie-Helene Blanchet ZumofenPublished in: Expert review of pharmacoeconomics & outcomes research (2024)
Baloxavir treatment resulted in the fewest influenza cases and was cost-effective versus oseltamivir or no antiviral treatment from a UK National Health Service perspective.